Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab Intervention and Diet Evaluation for Pouchitis
NCT06916390Phase 4Recruiting
- Sponsor
- UZ Leuven
- Start
- Apr 2026
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of guselkumab in pouchitis (2 arms), sponsored by UZ Leuven. Primary endpoint: Percentage of subjects achieving clinical remission at 16 weeks. Started Apr 2026; status: recruiting.
02
Drugs
guselkumab
03
Conditions
pouchitis
Beyond the preview
Go deeper on NCT06916390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916390.